[go: up one dir, main page]

MX2025004075A - Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos - Google Patents

Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos

Info

Publication number
MX2025004075A
MX2025004075A MX2025004075A MX2025004075A MX2025004075A MX 2025004075 A MX2025004075 A MX 2025004075A MX 2025004075 A MX2025004075 A MX 2025004075A MX 2025004075 A MX2025004075 A MX 2025004075A MX 2025004075 A MX2025004075 A MX 2025004075A
Authority
MX
Mexico
Prior art keywords
pcv3
porcine circovirus
vaccines
production
circovirus type
Prior art date
Application number
MX2025004075A
Other languages
English (en)
Inventor
Arun Iyer
Luis Alejandro Hernandez
Abby Patterson
Bailey Arruda
Luis Gabriel Gimenez-Lirola
David Michael Anstrom
Eric M Vaughn
Pineiro Pablo E Pineyro
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Univ Iowa State Res Found Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh, Univ Iowa State Res Found Inc filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of MX2025004075A publication Critical patent/MX2025004075A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona al uso de una composición inmunogénica que comprende un antígeno de circovirus porcino tipo 3 (PCV3) para el tratamiento de varias manifestaciones clínicas (enfermedades). De preferencia, las manifestaciones clínicas se asocian con una infección de PCV3.
MX2025004075A 2019-04-04 2021-09-30 Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos MX2025004075A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962829400P 2019-04-04 2019-04-04
PCT/US2020/026930 WO2020206452A1 (en) 2019-04-04 2020-04-06 Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof

Publications (1)

Publication Number Publication Date
MX2025004075A true MX2025004075A (es) 2025-06-02

Family

ID=70680577

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021012051A MX2021012051A (es) 2019-04-04 2020-04-06 Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos.
MX2025004075A MX2025004075A (es) 2019-04-04 2021-09-30 Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021012051A MX2021012051A (es) 2019-04-04 2020-04-06 Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos.

Country Status (13)

Country Link
US (3) US11701419B2 (es)
EP (1) EP3953370A1 (es)
JP (1) JP7762565B2 (es)
KR (1) KR20220004967A (es)
CN (1) CN114222579A (es)
AU (2) AU2020256283B2 (es)
BR (1) BR112021019859A2 (es)
CA (1) CA3136141A1 (es)
CL (1) CL2021002582A1 (es)
MX (2) MX2021012051A (es)
PH (1) PH12021552477A1 (es)
WO (1) WO2020206452A1 (es)
ZA (1) ZA202107428B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2744193C2 (ru) 2015-10-16 2021-03-03 Канзас Стейт Юниверсити Рисерч Фаундейшн Иммуногенные композиции для иммунизации свиней против цирковируса типа 3 и способы их получения и применения
KR20220004967A (ko) * 2019-04-04 2022-01-12 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 돼지 써코바이러스 3형 (pcv3) 백신, 및 이의 제조 및 용도
CN115028688B (zh) * 2022-04-28 2024-04-16 山东信得科技股份有限公司 PCV3 Cap蛋白抗原肽、抗体及PCV3检测用免疫组化试剂盒
CN115960250B (zh) * 2022-08-06 2025-09-09 武汉科前生物股份有限公司 一种重组猪圆环病毒3型三聚体蛋白及其制备方法与应用
CN119019544B (zh) * 2024-08-09 2025-10-17 浙江理工大学 一种猪圆环病毒3型抗原检测试剂条及制备方法和应用
CN119307516A (zh) * 2024-11-15 2025-01-14 扬州大学 一种重组猪圆环病毒3型cap基因片段及其在双抗原夹心elisa抗体检测中的应用
CN119780429B (zh) * 2024-12-27 2025-12-26 华派生物技术(集团)股份有限公司 一种提高猪圆环病毒2型Cap蛋白抗原琼扩检测灵敏度的方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3479708A (en) 1968-05-15 1969-11-25 Edson P Foster Felting needle
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
EP0322417A1 (en) 1986-09-08 1989-07-05 Applied Biotechnology, Inc. Empty viral capsid vaccines
ES2026827A6 (es) 1991-03-26 1992-05-01 Ercros Sa Procedimiento para la produccion de una vacuna subunidad contra el parvovirus porcino.
ES2069435T4 (es) 1991-06-06 1997-06-16 Stichting Centr Diergeneeskund Composicion de vacuna para vacunar animales, en concreto mamiferos y mas concretamente cerdos o cochinos.
DE69214657T2 (de) 1991-08-26 1997-04-17 David Allen Benfield Vakzine gegen und diagnosemethode für das schweine-unfruchtbarkeits- und atmungs-syndrom (suas)
US6042830A (en) 1992-08-05 2000-03-28 Boehringer Ingelheim Vetmedica, Inc. Viral agent associated with mystery swine disease
WO1993006211A1 (en) 1991-09-16 1993-04-01 Collins James E Vaccine for mystery swine disease and method for diagnosis thereof
HU220113B (hu) 1991-10-14 2001-11-28 Akzo N.V. Sertések reproduktív és légzőszervi tünetegyüttese elleni vakcina, eljárás előállítására és alkalmazása
DE69522984T2 (de) 1994-04-11 2002-04-25 Akzo Nobel Nv Europäische Vakzinstämme des Fortplanzungs-Atmungs-Syndromsvirus des Schweins
ATE268783T1 (de) 1995-03-14 2004-06-15 Akzo Nobel Nv Expression in der selben zelle von polypeptide vom schweinen reproduktiven und respiratorischen syndrom
DE69704011T2 (de) 1996-10-09 2001-06-07 Akzo Nobel Nv Europäische Vakzinstämme des Fortplanzungs-Atmungs-Syndromsvirus des Sweins (PRRSV)
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
WO2004069152A2 (en) 2002-05-03 2004-08-19 Massachusetts Institute Of Technology Δ4,5 glycuronidase and uses thereof
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
EP2460819A3 (en) 2004-12-30 2013-01-09 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
ES2572736T3 (es) 2005-12-29 2016-06-02 Boehringer Ingelheim Vetmedica, Inc. Uso de una composición inmunógena para atenuar síntomas clínicos en cerdos
AU2007333857B2 (en) 2006-12-15 2014-05-15 Boehringer Ingelheim Animal Health USA Inc. Treatment of pigs with PCV2 antigen
AU2008314485B9 (en) 2007-10-15 2015-02-26 Jingang Medicine (Australia) Pty Ltd Expression system for modulating an immune response
EP2328919A2 (en) * 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
BRPI0919473A2 (pt) * 2008-09-26 2017-08-29 Oncomed Pharm Inc Agentes de ligação frizzled e usos dos mesmos
UA117272C2 (uk) 2011-02-17 2018-07-10 Бьорінгер Інгельхайм Ветмедіка Гмбх Новий європейський штам prrsv
CN104288760A (zh) 2013-07-18 2015-01-21 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
RU2744193C2 (ru) * 2015-10-16 2021-03-03 Канзас Стейт Юниверсити Рисерч Фаундейшн Иммуногенные композиции для иммунизации свиней против цирковируса типа 3 и способы их получения и применения
EA201991065A1 (ru) 2016-11-03 2019-11-29 Вакцина против свиного парвовируса
CN108619503A (zh) 2017-03-24 2018-10-09 华南农业大学 一种猪圆环病毒基因工程亚单位疫苗及其制备方法与应用
CN108785667B (zh) 2017-04-28 2021-04-27 普莱柯生物工程股份有限公司 一种猪圆环病毒3型免疫原性组合物、制备方法和应用
CN109010818B (zh) 2017-06-09 2021-11-09 普莱柯生物工程股份有限公司 一种预防和/或治疗猪圆环病毒感染的二联疫苗组合物及其制备方法和应用
CN109125719B (zh) * 2017-06-19 2022-06-14 普莱柯生物工程股份有限公司 一种含猪圆环病毒3型、猪圆环病毒2型抗原的免疫原性组合物及其应用
CN109125720B (zh) * 2017-06-19 2021-11-09 普莱柯生物工程股份有限公司 一种含猪圆环病毒3型抗原的免疫原性组合物及其应用
CN108159409A (zh) * 2017-12-25 2018-06-15 南京大爻网络科技有限公司 一种猪圆环病毒3型Cap蛋白疫苗及其制备方法和应用
CN108359677A (zh) * 2018-02-01 2018-08-03 福建农林大学 提高猪圆环病毒2型和3型Cap蛋白串联表达效率的方法
CA3102685A1 (en) * 2018-06-11 2019-12-19 Ceva Sante Animale Vaccination against porcine circoviruses
CN109053896B (zh) * 2018-07-03 2021-08-17 青岛明勤生物科技有限公司 一种猪圆环病毒二价基因工程疫苗
CN108823231B (zh) * 2018-07-09 2022-05-31 荣俊 一种猪圆环病毒3型基因工程亚单位疫苗及其制备方法
CN109207441B (zh) 2018-08-12 2022-05-27 扬州大学 重组杆状病毒表达猪圆环病毒3型Cap蛋白及其构建方法与引物
CN109207522B (zh) 2018-08-12 2022-05-27 扬州大学 表达猪圆环病毒3型截短Cap蛋白重组杆状病毒及其构建方法与引物
CN109550045B (zh) * 2018-12-26 2023-01-31 哈药集团生物疫苗有限公司 猪圆环病毒3型、猪细小病毒和猪流感三联灭活疫苗及其制备方法
CN109852622B (zh) 2019-01-18 2022-05-27 南京农业大学 一种可溶性PCV3Cap蛋白及其编码基因和应用
KR20220004967A (ko) * 2019-04-04 2022-01-12 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 돼지 써코바이러스 3형 (pcv3) 백신, 및 이의 제조 및 용도

Also Published As

Publication number Publication date
CL2021002582A1 (es) 2022-07-22
BR112021019859A2 (pt) 2022-02-15
MX2021012051A (es) 2022-01-18
US20210128712A1 (en) 2021-05-06
ZA202107428B (en) 2023-12-20
US11896659B2 (en) 2024-02-13
AU2020256283A1 (en) 2021-11-18
EP3953370A1 (en) 2022-02-16
KR20220004967A (ko) 2022-01-12
JP2022527627A (ja) 2022-06-02
US12433942B2 (en) 2025-10-07
AU2020256283A8 (en) 2024-01-11
US20240226264A1 (en) 2024-07-11
JP7762565B2 (ja) 2025-10-30
US11701419B2 (en) 2023-07-18
CN114222579A (zh) 2022-03-22
WO2020206452A1 (en) 2020-10-08
AU2020256283B2 (en) 2025-08-14
US20230302113A1 (en) 2023-09-28
PH12021552477A1 (en) 2022-07-18
AU2025267386A1 (en) 2026-01-29
CA3136141A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
MX2025004075A (es) Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos
MX2020003995A (es) Nuevas moleculas de acido nucleico artificiales.
MX2018014573A (es) Vacuna contra el virus del zika.
CO2021005226A2 (es) Nuevos compuestos antihelmínticos
CO2022001210A2 (es) Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes
BR112018068748A2 (pt) composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto
CO2018005361A2 (es) Formulaciones inyectables de toxina botulínica y sus métodos de uso que poseen efecto terapéutico o cosmético de larga duración
AR120057A1 (es) Composiciones neoantigénicas y usos de estas
MX2009008577A (es) Prevencion y tratamiento contra la enfermedad asociada a arcovirus porcion sub-clinica.
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
CU20170009A7 (es) 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas
UY32812A (es) Anticuerpos humanos de alta afinidad para angiopoyetina -2 humana.
MX2019008564A (es) Composiciones inmunogenicas para su uso en vacunas neumococicas.
BRPI1013780A2 (pt) composições para imunização contra staphylococcus aureus.
BR112022004397A2 (pt) Composições para tratamento bucal que compreendem beta ácidos de lúpulo e aminoácidos
AR081809A1 (es) Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas
MX2019005136A (es) Vacuna contra el parvovirus porcino y el virus del sindrome respiratorio reproductivo porcino y metodos de produccion de esta.
CL2020002915A1 (es) Composiciones para el tratamiento de condiciones de la piel
MX2021012695A (es) Vacuna de subunidad del virus de la fiebre porcina clasica (csfv).
CO2020007601A2 (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis
CO2021010786A2 (es) Toxinas apxia, apxiia y apxiiia inactivadas
MX2023012530A (es) Composición y metodos de vacuna adyuvada.
MX420767B (es) Proteina de union al factor h modificada
CL2021002430A1 (es) Formulación de tableta vaginal
AR115617A1 (es) Composición cosmética para el tratamiento de las fibras de queratina